Effectiveness of bivalent and quadrivalent human papillomavirus vaccination in Luxembourg by Latsuzbaia, Ardashel et al.
Contents lists available at ScienceDirect
Cancer Epidemiology
journal homepage: www.elsevier.com/locate/canep
Effectiveness of bivalent and quadrivalent human papillomavirus
vaccination in Luxembourg
Ardashel Latsuzbaiaa,⁎, Marc Arbynb, Jessica Tappa, Marc Fischerc, Steven Weyersd,
Pascale Pesche, Joël Mossonga
a Epidemiology and Microbial Genomics, National Health Laboratory, L-3555 Dudelange, Luxembourg
bUnit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, 1050 Brussels, Belgium
cNational Center of Pathology, National Health Laboratory, L-3555 Dudelange, Luxembourg
dDepartment of Obstetrics and Gynecology, Ghent University Hospital, 9000 Ghent, Belgium
e Family Planning, Luxembourg, L-1531 Luxembourg











A B S T R A C T
Background: In Luxembourg, the human papillomavirus (HPV) vaccination program introduced in 2008, pro-
vided either bivalent (BV) or quadrivalent (QV) vaccines to girls aged 12–17 years. Here, we estimate the ef-
fectiveness of BV and QV vaccines combined and separately in reducing type-specific HPV prevalence eight years
after the introduction of the vaccination program.
Methods: A cross-sectional prevalence study was conducted among women aged 18–29 years in 2015-2017.
Seven hundred sixteen participants were recruited at family planning centres or private gynaecology practices in
Luxembourg. Vaccination records were verified in the social security database. Cervical samples were tested
using the Anyplex II HPV28 assay. Vaccine effectiveness was estimated using logistic regression.
Results: In total, 363/716 (50.7%) participants were HPV positive with any HPV and 209/716 (29.2%) with
carcinogenic HPV genotypes. HPV vaccination offered high protection against HPV16/18 (adjusted odds ratio
(AOR)= 0.13; 95% CI 0.03-0.63), HPV6/11 (AOR=0.16; 95% CI 0.05-0.48) and cross-protection against
HPV31/33/45 (AOR=0.41; 95% CI 0.18-0.94). The AORs were generally enhanced when only considering
vaccination before sexual debut corresponding to AORs: 0.05 (95% CI 0.00-0.88), 0.08 (95% CI 0.02-0.36) and
0.20 (0.06-0.65) against HPV16/18, HPV6/11 and HPV31/33/45, respectively. We observed significant pro-
tection against carcinogenic genotypes included in nonavalent vaccine for BV (AOR=0.29; 95% CI 0.13-0.67),
but not for QV (AOR=0.81; 95% CI 0.47–1.40) (heterogeneity Chi2 P= 0.04).
Conclusions: Our study suggests high effectiveness of HPV vaccination against HPV6/11, HPV16/18 and a cross-
protection against HPV31/33/45. Vaccination effectiveness was slightly higher for women vaccinated before
sexual debut.
1. Introduction
Human papillomavirus (HPV) is the most common sexually trans-
mitted pathogen worldwide and the principal cause of cervical cancer
[1]. HPV genotypes have been classified into three groups according to
their oncogenic potential; carcinogenic group 1 (16/18/31/33/35/39/
45/51/52/56/58/59), probable/possible carcinogenic group 2 (26/30/
34/53/66/67/68/69/70/73/82/85/97) and group 3 (6/11 and others
not classifiable as carcinogenic to humans) [2]. Genotypes 16/18 are
responsible for 72% and genotypes 31/33/45/52/58 for an additional
18% of HPV-related cancers [3]. Genotypes 6/11 account for 90% of
genital wart cases [4].
Three prophylactic HPV vaccines are currently available: bivalent
vaccine (BV) protecting against genotypes 16/18, quadrivalent vaccine
(QV) protecting against genotypes 6/11/16/18, and nonavalent vaccine
protecting against genotypes 6/11/16/18/31/33/45/52/58. By
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February 2019, 92 countries or territories had introduced HPV vacci-
nation programmes distributing over 270 million vaccine doses during
the last decade [5,6]. A significant reduction in the prevalence of vac-
cine-related and non-vaccine genotypes has been reported in vaccine
trials and observational studies [7–12]. HPV vaccines have been proven
to be effective against cervical lesions and genital warts and have thus
the potential to prevent cervical and anogenital HPV-related cancers
[12–16].
In Luxembourg, the national HPV vaccination programme was in-
troduced in 2008, offering the choice of either BV or QV vaccine to
12–17 year old girls free of charge. The vaccines were delivered by private
physicians with the three-dose schedule over a 6-month interval. In 2015,
the vaccination schedule changed offering only two doses of BV vaccine
separated by 6 months [17]. In previous work we showed that overall
vaccination coverage with at least one dose was moderately high in Lux-
embourg, reaching 62% of women born between 1991 and 2003 [17].
The primary aim of this study was to estimate the effectiveness of
the HPV vaccination programme in Luxembourg 8 years after im-
plementation based on HPV prevalence in vaccinated and unvaccinated
women. The secondary aim was to estimate the effectiveness of bivalent
and quadrivalent vaccines separately. To our knowledge, this is one of
the first studies assessing the effectiveness of BV and QV vaccines in the
same population setting.
2. Methods
2.1. Study design and epidemiological data collection
A cross-sectional prevalence study was conducted from November
2015 until December 2017 in Luxembourg. Women, attending regular
cervical cancer screening or seeking sexual health service at family
planning centres (http://www.planningfamilial.lu/) or private gynae-
cology practices were recruited if they were sexually active and be-
longed to the age group 18–29 years. Participants signed an informed
consent form and completed a questionnaire on vaccination status and
sexual behaviour (Supplement 1). To ascertain vaccination status,
vaccination records consisting of vaccination dates and type of vaccine
(BV or QV) were obtained from the social security database and linked
with the self-reported questionnaire, HPV test and cytology results
using unique national personal identifiers. Vaccination status was de-
fined in four categories as follows: unvaccinated (no evidence of vac-
cination according to questionnaire and social security records), vac-
cinated with at least two BV doses verified by social security records,
vaccinated with at least two QV doses verified by social security records
and other vaccinated (i.e. self-report only, one verified dose only or
different vaccine types according to social security records). The vac-
cinated category included participants who received at least two doses
of BV or QV vaccines regardless of the interval between the doses and
vaccination age. Only 10% of the participants were vaccinated with 2
doses above the recommended vaccination age (range 15–18 years) or
having a between dose interval lower than 6 months.
2.2. Cytology
Cervical samples were collected by gynaecologists with a cervical
broom and placed in a vial containing PreservCyt medium for liquid-
based cytology according to European Guidelines [18]. Samples were
examined according to the ThinPrep Pap Test and Imaging System
(Hologic, Bedford, MA, USA) and interpreted according to the Bethesda
2001 nomenclature: negative for intraepithelial lesions and malig-
nancies (NILM), atypical squamous cells of undetermined significance
(ASC-US), atypical glandular cells not otherwise specified (AGC-NOS),
low-grade squamous intraepithelial lesions (LSIL), atypical squamous
cells of undetermined significance, in which a high-grade squamous
intraepithelial lesion cannot be excluded (ASC-H), and high-grade
squamous intraepithelial lesions (HSIL) [19].
2.3. HPV genotyping
DNA extraction from ThinPrep samples was performed using the
QIAamp DNA mini kit according to the manufacturer’s instructions
(Qiagen, Hilden, Germany) [20]. HPV detection and genotyping were
performed with the Anyplex II HPV28 assay (Seegene, Seoul, South
Korea) based on a pilot study, which is based on multiplex real-time
PCR targeting L1 gene [21]. The Anyplex II HPV28 assay simulta-
neously detects and identifies 28 HPV genotypes including all of the
carcinogenic and probable/possibly carcinogenic genotypes [2]. Am-
plification was performed in two multiplex reactions on a CFX96 real-
time thermocycler (Bio-Rad, Hercules, CA; 5 μL input volume for both
multiplex reaction). Data recording and interpretation (automated with
the Seegene viewer software) were performed according to the manu-
facturer instructions [21].
2.4. Statistical analysis
Statistical analysis was performed using STATA 14 (College Station,
Texas, USA). Differences between proportions were assessed by
Pearson's Chi2 test. We used stepwise logistic regression analysis to
evaluate the association between potential risk/protective factors and
HPV infection. As HPV infection with any type was significantly asso-
ciated with the number of lifetime sexual partners and last partnership
duration (p < 0.05), these variables were controlled for in the multi-
variable logistic regression model to study the effect of vaccination
status on HPV prevalence. Although age was not significantly asso-
ciated with HPV in the stepwise logistic regression, we included the
variable in the main analysis, since it is a strong epidemiological pre-
dictor of HPV infection [22]. We studied the effect of each vaccine
separately and of HPV vaccination jointly. Adjusted odds ratios (AOR)
estimated from the logistic regression model were used to calculate
vaccine effectiveness (VE) as follows: VE = (1-AOR) * 100 [8,23,24].
Missing values were included in the model as a separate category.
3. Results
3.1. Characteristics of study participants
Overall 716 female study participants with a mean age of 22.3 years
were recruited, of which 654 (91.3%) at family planning and 62 (8.7%)
at private gynaecology practices. Four hundred seven (56.8%) were
Luxembourgish, 188 (26.3%) had Portuguese nationality and 121
(16.9%) had other nationalities reflecting the population composition
of this age group in Luxembourg [25]. The mean age at sexual debut
was 16.7 years, and 531 (76.5%) of 694 participants reported more
than one lifetime sexual partner. The characteristics of the study po-
pulation by vaccination status are presented in Table 1.
3.2. Vaccination status
Overall, 401 (56.0%) participants reported having been vaccinated,
248 (34.6%) reported to be unvaccinated and 67 (9.4%) did not know
their vaccination status. Vaccination with at least two doses of the same
vaccine was verified in the social security database for 347 (48.5%)
participants corresponding to 86.4% of women who reported to be
vaccinated. Among the 347 vaccinated women with two verified doses
of the same vaccine, 131 (37.8%) were vaccinated with BV and 216
(62.2%) were vaccinated with QV. An additional 137 (19.1%) of par-
ticipants had some evidence of vaccination (self-report or vaccine dose
recorded), but two doses of the same vaccine could not be verified in
the social security database, including 32 (4.5%) participants with a
single dose or two doses with different vaccines (Table 2).
The proportion of participants who received three doses did not
differ significantly (p= 0.879) between BV (115/131, 87.8%) and QV
recipients (185/216, 85.6%). Similarly, the proportion of participants
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Table 1
Characteristics of study population by vaccination status.
Total N
(col %)







Total 716 232 (32.4) 137 (19.1) 131 (18.3) 216 (30.2)
Vaccinated before sexual debut 97 (74.0) 162 (75.0)
Age < 0.001 <0.001 <0.001
18-20 244 (34.1) 34 (14.7) 50 (36.5) 71 (54.2) 89 (41.2)
21-23 234 (32.7) 65 (28.0) 39 (28.5) 43 (32.8) 87 (40.3)
24+ 238 (33.2) 133 (57.3) 48 (35.0) 17 (13.0) 40 (18.5)
Mean age (range) 22.3 (18-29) 24.2 (18-29) 22.2 (18-29) < 0.001 20.6 (18-26) <0.001 21.3 (18-26) <0.001
Nationality 0.120 0.244 <0.001
Luxembourgish 407 (56.8) 129 (55.6) 61 (44.5) 75 (57.3) 142 (65.7)
Portuguese 188 (26.3) 54 (23.3) 40 (29.2) 37 (28.2) 57 (26.4)
Other 121 (16.9) 49 (21.1) 36 (26.3) 19 (14.5) 17 (7.9)
Language 0.191 0.298 0.068
French 503 (70.3) 151 (65.1) 99 (72.3) 93 (71.0) 160 (74.1)
German 152 (21.2) 57 (24.6) 23 (16.8) 28 (21.4) 44 (20.4)
Others 61 (8.5) 24 (10.3) 15 (10.9) 10 (7.6) 12 (5.5)
Age of sexual debut
< 16 178 (24.9) 61 (26.3) 28 (20.4) 0.136 31 (23.7) 0.008 58 (26.9) 0.144
16-17 329 (46.0) 89 (38.4) 67 (48.9) 72 (55.0) 101 (46.8)
≥18 197 (27.5) 76 (32.8) 39 (28.5) 27 (20.6) 55 (25.5)
Mean age (range) 16.7 (12-29) 16.9 (12-26) 16.8 (13-29) 0.728 16.4 (13-21) 0.036 16.5(12-24) 0.037
Lifetime sexual partners 0.011 <0.001 <0.001
0-2 307 (42.9) 72 (31.0) 58 (42.3) 68 (51.9) 109 (50.5)
3-4 213 (29.8) 69 (29.7) 45 (32.9) 40 (30.5) 59 (27.3)
≥5 174 (24.3) 84 (36.2) 30 (21.9) 20 (15.3) 40 (18.5)
Duration with last partner in years 0.465 0.065 0.712
0-1 267 (37.3) 82 (35.3) 51 (37.2) 56 (42.8) 78 (36.1)
2-3 186 (26.0) 54 (23.3) 40 (29.2) 34 (26.0) 58 (26.9)
≥4 186 (26.0) 68 (29.3) 35 (25.6) 24 (18.3) 59 (27.3)
Mean duration in years (range) 2.7 (0-13) 3.0 (0-13) 2.8 (0-11) 0.524 2.3 (0-10) 0.036 2.6 (0-9) 0.165
Last partner age 0.001 <0.001 <0.001
<21 183 (25.6) 35 (15.1) 38 (27.7) 52 (39.7) 58 (26.9)
22-25 273 (38.1) 74 (31.9) 51 (37.2) 52 (39.7) 96 (44.4)
≥26 236 (33.0) 115 (49.6) 45 (32.9) 20 (15.3) 56 (25.9)
Mean age (range) 24.3 (16-45) 26.0 (16-45) 24.1 (16-41) < 0.001 22.4 (17-36) <0.001 23.7 (16-37) <0.001
Absolute age difference with last partner in years 0.240 0.259 0.998
0-1 290 (40.5) 89 (38.4) 63 (46.0) 55 (42.0) 83 (38.4)
2-3 197 (27.5) 62 (26.7) 38 (27.7) 39 (29.8) 58 (26.9)
≥4 205 (28.6) 73 (31.5) 33 (24.1) 30 (22.9) 69 (31.9)
Mean absolute difference (range) 2.8 (0-18) 3.0 (0-18) 2.6 (0-17) 0.274 2.4 (0-13) 0.039 2.9 (0-14) 0.755
Condom use 0.825 0.874 0.367
Never 184 (25.8) 57 (24.7) 38 (27.9) 32 (24.4) 57 (26.4)
Sometimes 277 (38.8) 96 (41.6) 58 (42.7) 50 (38.2) 73 (33.8)
Often 138 (19.3) 44 (19.0) 22 (16.2) 26 (19.9) 46 (21.3)
Always 115 (16.1) 34 (14.7) 18 (13.2) 23 (17.6) 40 (18.5)
Smoking status 0.327 0.904 0.089
Never 448 (62.6) 141 (60.8) 77 (56.2) 82 (62.6) 148(68.5)
Sometimes 69 (9.6) 23 (9.9) 16 (11.7) 10 (7.6) 20 (9.3)
Often 41 (5.7) 18 (7.8) 6 (4.4) 11 (8.4) 6 (2.8)
Daily 158 (22.1) 50 (21.5) 38 (27.7) 28 (21.4) 42 (19.4)
Abbreviations: BV, bivalent vaccine; QV, quadrivalent vaccine;
P-values are reported comparing each category (BV, QV and other vaccinated) to unvaccinated category using Chi2 test. Mean values were compared using t-test.
Missing values were excluded from the analysis. Data are no. (%) of participants, unless otherwise indicated.
Table 2
Comparison of self-reported and verified vaccination status from the social security database among study participants.











Unvaccinated 232 (100) 6 (4.4) 4 (3.1) 6 (2.8) 248 (34.6)
Unknown vaccination status 0 (0) 48 (35.0) 10 (7.6) 9 (4.2) 67 (9.4)
vaccinated with QV 0 (0) 24 (17.5) 2 (1.5) 93 (43.0) 119 (16.6)
vaccinated with BV 0 (0) 13 (9.5) 60 (45.8) 3 (1.4) 76 (10.6)
Vaccinated, unknown type 0 (0) 46 (33.6) 55 (42.0) 105 (48.6) 206 (28.8)
Total 232 (100) 137 (100) 131 (100) 216 (100) 716 (100)
Abbreviations: BV, bivalent vaccine; QV, quadrivalent vaccine;
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who started vaccination before sexual debut did not differ significantly
(p=0.940) between BV (97/131, 74%) and QV recipients (162/216,
75%).
3.3. HPV prevalence
In total, 363 (50.7%) participants were positive for at least one of
the 28 HPV genotypes tested and 199 (27.8%) were infected with more
than one genotype. HPV prevalence was similar (p=0.334) in verified
2-dose vaccinated women (161/347, 46.4%) as in unvaccinated women
(124/232, 53.5%). HPV prevalence was similar (p=0.434) between
verified 2-dose recipients of BV (55/131, 42%) and QV (106/216,
49.1%) (Supplementary Table 1). The average number of HPV geno-
types per participant was significantly lower in verified 2-dose re-
cipients of BV (0.78) than in recipients of QV (1.11, p=0.035) or than
in unvaccinated participants (1.15, p=0.016). In total, 773 genotypes
were detected with 1.08 average number of genotypes per participants.
Prevalence of 12 carcinogenic (group 1) genotypes was 209
(29.2%). We did not observe a significant difference (p= 0.347) in the
prevalence of carcinogenic genotypes in verified 2-dose vaccinated
women (91/347, 26.2%) and unvaccinated women (72/232, 31%). The
prevalence of carcinogenic types also did not differ (p=0.229) be-
tween BV (29/131, 22.1%) and QV recipients (62/216, 28.7%). The
average number of carcinogenic HPV genotypes per participant was
significantly lower in verified 2-dose recipients of BV (0.28) than in
unvaccinated participants (0.45, p= 0.030), but not compared to ver-
ified 2-dose recipients of QV (0.39, p= 0.070).
The three most frequently observed carcinogenic genotypes in
vaccinated women were 51 (6.3%), 59 (6.3%) and 58 (5.5%) compared
to 16 (6.9%), 51 (6.9%), 31 (6.5%) in unvaccinated women (Fig. 1,
Supplementary Tables 1 and 2). Crude type-specific prevalences of
genotypes 16, 31 and 33 (p < 0.05) were significantly lower in vac-
cinated compared to unvaccinated participants (Supplementary Tables
1 and 2).
3.4. Cytological results
Two samples could not be analysed due to unsatisfactory specimen
quality. Prevalence of cytological abnormalities was as follows; 23/714
(3.2%) ASC-US, 41/714 (5.7%) LSIL, 1/714 (0.1) ASC-H, 1/714 (0.1%)
HSIL, and 648/714 (90.8%) were negative for abnormal lesions. No
significant difference of abnormal lesions (ASCUS+) was observed
between vaccinated and unvaccinated populations (p=0.293)
(Supplementary Table 3).
3.5. Effectiveness of HPV vaccination and sexual debut
After controlling for sexual activity and age the protection induced
by two doses of the same vaccine against infection with genotypes 16/
18 and 6/11 was 0.13 (95% CI 0.03-0.63) and 0.16 (95% CI 0.05-0.48),
respectively (Table 3). We observed significant cross-protection against
genotypes 31/33/45 (AOR=0.41; 95% CI 0.18-0.94) in verified 2-dose
recipients. The AOR associated with carcinogenic genotypes not in-
cluded in the nonavalent vaccine (35/39/51/56/59) was marginally
non-significant (AOR=1.65; 95% CI 0.97–2.81). The corresponding
AORs were generally enhanced when only considering vaccination
before sexual debut: 0.05 (95% CI 0.00-0.88), 0.08 (95% CI 0.02-0.36),
0.20 (95% CI 0.06-0.65) against genotypes 16/18, 6/11 and 31/33/45,
respectively.
There was no evidence of vaccination impact on other carcinogenic
genotypes (35/39/51/52/56/58/59) not covered by vaccines and not
cross-protection types (AOR=1.35; 95% CI 0.85–2.14) (Table 3).
Other type-specific AORs are presented in Supplementary Table 2.
3.6. BV and QV vaccine effectiveness
Protection against genotypes 16/18 was 0.19 (95% CI 0.02–1.62)
and 0.10 (95% CI 0.01-0.82) for BV and QV vaccine recipients, re-
spectively (Table 4). Significant protection against nonavalent vaccine
types was 0.29 (95% CI 0.13-0.67) for BV recipients compared to 0.81
(95% CI 0.47–1.40) for QV (heterogeneity Chi2 p=0.031). There was
no evidence of protection with ether vaccine against genotypes not
covered by vaccines and not cross-protection types (35/39/51/52/56/
58/59): BV (AOR=1.04; 95% CI 0.58–1.87) and QV (AOR=1.53;
95% CI 0.94–2.50) (Table 4). Type-specific AORs are presented in
Supplementary Table 4.
4. Discussion
To our knowledge, our study is the first to provide type-specific HPV
prevalence in Luxembourg and to estimate the effectiveness of BV and
QV vaccines combined and separately in the same population. Our
findings suggest that the vaccination programme already had a sub-
stantial impact on HPV genotype distribution in vaccinated young
women 8 years after its introduction.
First, the prevalence of HPV types included in the vaccine and some
other non-vaccine genotypes is lower in vaccinated young women in-
dependent of vaccine type. Our results suggest that VE against certain
HPV genotypes not included in the vaccines (i.e. cross-protection) is
higher in BV compared to QV recipients. In addition, the prevalence of
nonavalent vaccine genotypes was significantly lower in BV compared
to QV recipients (Supplementary Table 1). A Cochrane review also
showed similar protection of BV and QV against cervical pre-cancers
related to types 16/18, but BV offered better protection against cervical
precancers overall [26]. Interestingly, immunogenicity studies reported
significantly higher antibody levels against vaccine and non-vaccine
types among BV recipients compared to QV [27–29].
Second, concerns have been raised that carcinogenic genotypes not
Fig. 1. Carcinogenic human papillomavirus prevalence
(95%CI) by vaccination status.
Abbreviations: BV, bivalent vaccine; CI, confidence interval;
QV, quadrivalent vaccine;
a12 HPV genotypes classified by International Agency for
Research on Cancer as carcinogenic to humans.
*Individual HPV types significantly associated with vaccina-
tion status in logistic regression model.
(Supplementary Table 3).
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included in the vaccines could potentially replace the niche occupied by
vaccine types [30]. In our study, we did not find a statistically sig-
nificant difference in the prevalence of carcinogenic genotypes in vac-
cinees and non-vaccinees. Similarly, several vaccine monitoring studies
and long-term follow-up of clinical trials have shown that HPV vaccines
do not induce type replacement [24,31–34]. Pooled analysis of the
Costa Rica and PATRICA trials evaluated 21,596 women (with 50%
vaccination coverage of BV) suggested that type replacement is unlikely
to occur in populations with low vaccination coverage. In addition, this
study suggested protection against oncogenic HPV types 35, 52, 58, and
68/73, as well as non-oncogenic types 6 and 70 [33]. This is incon-
sistent with a meta-analysis by Mesher et al. reporting a significant
increase of genotype 39 and 52 in the post-vaccination era [35] and a
community-randomised trial by Gray et al. showing significantly in-
creased prevalence ratio of genotypes 39 and 51 in BV recipients [32].
In both studies, results were inconsistent in different age groups and
increases could have different explanations, therefore both studies re-
ported no clear evidence of type-replacement. Another potential ex-
planation of this phenomenon could be the so-called “unmasking” ef-
fect. It occurs when consensus primer PCR assays detect non-vaccine
carcinogenic HPV genotypes (e.g. type 52) more frequently in absence
of HPV16 or 18 due to primer competition [30,36]. However, Anyplex
is a type-specific multiplex PCR not based on consensus primers and is
therefore less prone to unmasking. During the WHO HPV LabNet Pro-
ficiency Study in 2013 and 2014, the Anyplex assay showed high
performance in detecting single and multiple infections at concentra-
tions of 5, 50 and 500 IU per 5 μl [21,37].
Third, our study also highlights that ascertainment of whether
vaccination occurred before sexual debut is relevant and should be
considered in future prevalence studies. Genotypes 16 and 18 were not
detected in women receiving two doses before sexual debut equivalent
to 100% effectiveness. Similarly, cross-protection against genotypes
31/33/45 was slightly higher for women vaccinated before sexual
debut compared to all vaccinated women. Our estimates of VE of 87%
against HPV16/18 (Table 3 and Supplementary Table 5) are in agree-
ment with a similar Belgian surveillance study where good protection
was observed among women aged 18–19 years, with decreasing effec-
tiveness in older women [7]. Even though a minority (24%) of women
were vaccinated after sexual debut, our results suggest a higher VE in
women vaccinated before sexual debut, in agreement with studies in
the Netherlands and Italy [23,24].
Interestingly, the prevalence of HPV18 was not significantly dif-
ferent across the groups; while the low case numbers may explain the
lack of significance, it could also be that the prevalence of HPV18 in all
groups was higher prior to vaccination program and may have dropped
due to herd protection. We have not observed such an effect for HPV16
given its higher prevalence and persistence. According to modelling
studies, herd protection effect might be stronger for HPV6, 11, 18
compared to HPV16 [38]. Studies from other countries with good
vaccine coverage have demonstrated declines in vaccine-type HPV
Table 3
Association between human papillomavirus infection and verified 2-dose vaccination status, considering all vaccinations and vaccinations before sexual debut.
HPV types HPV Prevalence N (%) Adjusteda OR vaccinated vs
unvaccinated






Vaccinated before sexual debut
(N=259)
AOR (95%CI) P-value AOR (95%CI) P-value
16/18 19 (8.2) 2 (0.6) 0 (0.0) 0.13 (0.03-0.63) 0.012 0.05 (0.00-0.88) 0.038
6/11 13 (5.6) 5 (1.4) 2 (0.8) 0.16 (0.05-0.48) 0.001 0.08 (0.02-0.36) 0.001
31/33/45b 25 (10.8) 11 (3.2) 4 (1.5) 0.41 (0.18-0.94) 0.034 0.20 (0.06-0.65) 0.007
nonavalentc 54 (23.3) 40 (11.5) 25 (9.7) 0.60 (0.34-1.02) 0.060 0.52 (0.29-0.94) 0.031
35/39/51/52/56/58/
59d
49 (21.1) 86 (24.8) 63 (24.3) 1.35 (0.85-2.14) 0.204 1.33 (0.81-2.20) 0.263
35/39/51/56/59e 32 (13.8) 65 (18.7) 48 (18.5) 1.65 (0.97-2.81) 0.065 1.68 (0.94-2.98) 0.078
Abbreviations: AOR, adjusted odds ratio; CI, confidence interval;
a OR adjusted for number of lifetime sexual partners, last partnership duration and age.
b Carcinogenic HPV genotypes, genetically related to HPV16/18.
c Carcinogenic HPV genotypes included in nonavalent vaccine.
d Carcinogenic HPV genotypes not included in BV/QV and not cross-protection types 31/33/45.
e Carcinogenic HPV genotypes not included in nonavalent vaccine.
Table 4
Association between human papillomavirus infections and verified 2-dose bivalent and quadrivalent vaccine recipients.







AOR (95%CI) P-value AOR (95%CI) P-Value P-Value
16/18 19 (8.2) 1 (0.8) 1 (0.5) 0.19 (0.02-1.62) 0.130 0.10 (0.01-0.82) 0.032 0.686
6/11 13 (5.6) 2 (1.5) 3 (1.4) 0.16 (0.04-0.76) 0.022 0.15 (0.04-0.58) 0.006 0.949
31/33/45b 25 (10.8) 2 (0.5) 9 (4.2) 0.19 (0.04-0.88) 0.034 0.54 (0.23-1.27) 0.159 0.246
nonavalentc 54 (23.3) 8 (6.1) 32 (14.8) 0.29 (0.13-0.67) 0.004 0.81 (0.47-1.40) 0.443 0.041
35/39/51/52/56/58/59d 49 (21.1) 28 (21.4) 58 (26.9) 1.04 (0.58-1.87) 0.892 1.53 (0.94-2.50) 0.088 0.321
35/39/51/56/59e 32 (13.4) 23 (17.6) 42 (19.4) 1.47 (0.76-2.84) 0.250 1.75 (1.00-3.07) 0.052 0.693
a OR adjusted for number of lifetime sexual partners, last partnership duration and age.
b Carcinogenic HPV genotypes, genetically related to HPV16/18.
c Carcinogenic HPV genotypes included in nonavalent vaccine.
d Carcinogenic HPV genotypes not included in BV/QV and not cross-protection types 31/33/45.
e Carcinogenic HPV genotypes not included in nonavalent vaccine.
f Inter vaccine heterogeneity was assessed using Pearson Chi2 test.
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prevalence even in unvaccinated women and men due to herd protec-
tion [12,39–43]. A study from Norway reported a 54% reduction of
vaccine genotypes in unvaccinated women due to herd protection [43].
Low prevalence of HPV18 in our study could be also explained by the
lower sensitivity of the assay for this particular genotype. However,
during the LabNet 2013/2014 study, all 14 laboratories using the
Anyplex correctly identified HPV genotypes 6, 11, 16 and 18 at con-
centrations of 5, 50 and 500 IU per 5 μl [37], and thus assay sensitivity
does not appear to be problematic for genotype 18 in particular.
One of the limitations of our study was the rather small sample size.
The study size was determined by budgetary and logistic constraints.
Nevertheless, power calculations a posteriori, showed that our sur-
veillance was sufficiently large to address protection of HPV vaccina-
tion against HPV16/18 infection and against cross-reacting types
HPV31/33/45 (Supplementary Table 7). Another limitation, which
could have an impact on representativeness, was the context of re-
cruitment mainly taking place in family planning centres where young
women seek sexual health services. Thus, by definition, sexual activity
levels in our study group are likely to be higher than in the general
population. Apart from different sexual behaviour, women attending
family planning might also have another socio-economic status, com-
pared to the general population, but we did not collect this information.
While we attempted to implicate private gynaecologists with study
recruitment, obtaining informed consent with questionnaires is very
challenging in this setting.
One of the strengths of our study was that self-reported vaccination
status could be verified using records from the social security database.
This allowed us to stratify vaccinated women in different categories ac-
cording to the strength of vaccination evidence. We created an extra
vaccination category which included women vaccinated with only one
dose or with self-reported vaccination status to keep information for these
participants. Even though the group classified as "others" is also a limita-
tion and represents 19% of the study population, this categorisation pro-
vided us with a more reliable ascertainment of actual vaccination status.
4.1. Conclusions
Our findings suggest high VE against vaccine genotypes 16/18 and
cross protection against genotypes 31/33/45 for 2-dose vaccine re-
cipients irrespective of vaccine type. VE was higher for women vacci-
nated before sexual debut, showing the importance of vaccination be-
fore exposure to HPV infection.
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